
Subject: Cyoctol, antiandrogen hemmt DHT ohne Nebenwirkungen seit 1989

Posted by [tricospanish](#) on Mon, 03 Oct 2011 20:10:00 GMT

[View Forum Message](#) <> [Reply to Message](#)

Cyoctol is a nonsteroidal, nonsystemic compound which competitively inhibits androgen binding to DHT-receptors in skin cells.

It is completely metabolized in the skin after topical application. Since male pattern baldness is an androgen-dependent phenomenon, the safety and efficacy of this local antiandrogen was evaluated in a double-blind, placebo controlled study in patients with early androgenetic alopecia.

This study was initially planned for 24 weeks but extended to 48 weeks after the availability of extended safety data from preclinical animal studies.

- 83% using cyoctol had an increase in hair counts in comparison to placebo
- 92% had either hair growth or an arrest of hairloss
- There was an 11,3% increase in mean hair counts.

File Attachments

1) [Cyoctol1.jpg](#), downloaded 408 times

TREATMENT CYOC

Richard

* Department of

† Chant

INTRODUCTION

Cyotol is a nonsteroidal, nonsystemic compound which competitively inhibits androgen binding to DHT-receptors in skin cells. It is completely metabolized in the skin after topical application. Since male pattern baldness is an androgen-dependent phenomenon, the safety and efficacy of this local antiandrogen was evaluated in a double-blind, placebo-controlled study in patients with early androgenetic alopecia. This study was initially planned for 24 weeks but extended to 48 weeks after the availability of extended safety data from preclinical animal studies.

METHODS

Patient Selection

- Healthy males age 18 to 50 years
- Dark hair
- Male pattern baldness classified as type III vertex, IV or V on Hamilton scale
- > 50 but < 500 hairs present in a 1-inch diameter target area on periphery of balding vertex
- No treatment for baldness for 6 months prior to commencing study

Treatment Procedures

Patients randomized to receive one of the following treatments:

- 0.01% Cyotol in 75%/25% ethanol-water solution
- 0.5% Cyotol in 75%/25% ethanol-water solution
- Placebo - 75%/25% ethanol-water solution

1-ml of medication applied BID with a Dab- O-Mat applicator to the scalp vertex



Safety Evaluations

Performed at Baseline and at 8, 16, 24 and 48 weeks

- Blood chemistry
- Hematology
- Hormone profiles (FSH, LH, DHEA, estradiol, total and free testosterone)
- Urinalysis

Scalp examination for cutaneous effects and history of symptoms at 8 week intervals

Efficacy Evaluations

Performed at Baseline and at 8 week intervals

- Manual hair counts
- Center of target area on scalp marked with a dot tattoo to identify the same area for evaluation at each visit.
- Hair counting under magnifying lens; repeated twice
- Photographs taken using standardized lighting and distance
- Computer-generated hair counts from photographs using an Image Processing and Analysis System (Quantex Corp., Sunnyvale, CA). Procedures described in Poster Presentation #67)